http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170084377-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_832231e56616a3e87c01de72bb8aaeba |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7004 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
| filingDate | 2016-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5eecfa10cbab616557e4e7610d3d8b8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3599667f250e373f1037d14d65a63ba3 |
| publicationDate | 2017-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20170084377-A |
| titleOfInvention | Pharmaceutical composition for enhancing anticancer efficacy of 2-deoxyglucose comprising T-type calcium channel inhibitor |
| abstract | The present invention relates to a pharmaceutical composition for enhancing the anticancer effect of 2-deoxyglucose which comprises T-type calcium channel inhibitor as an active ingredient. The present invention relates to a pharmaceutical composition for enhancing the anticancer effect of 2-deoxyglucose, Was synergized with G1 phase and the S-phase was temporarily increased after the drug was removed to increase the 2-DG uptake of the tumor to increase the therapeutic effect. Therefore, mibefradil is expected to be an effective cancer treatment strategy as a combination therapy for chemotherapy. |
| priorityDate | 2016-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 83.